Lyon (France), May 23, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells, announces that it has published the exemption document relating to the merger project with Pherecydes.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]